MirZyme Therapeutics is focused on the development and commercialisation of targeted therapeutics to prevent preeclampsia.
MirZyme has several global patents granted. These relate to a pipeline of product offerings that address the unmet medical needs of patients with preeclampsia. Uniquely, MirZyme will be the first to provide targeted therapeutics with a companion diagnostic test for the disorder.
Professor Ahmed holds the position of Executive Chairman of the Board and oversees the vision and direction of the company. He has hand selected a great team to work within MirZyme, and collectively, they are developing a cure for preeclampsia.
"Out of clutter find simplicity; From discord find harmony; In the middle of difficulty lies opportunity."
Solving the problem
Professor Ahmed's team at MirZyme is working towards developing and commercialising diagnostics and drugs to prevent pregnancy complications, in particular preeclampsia and fetal growth restriction.